Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pathogenic autoantibodies in systemic sclerosis.

Armando Gabrielli1, Silvia Svegliati, Gianluca Moroncini

  • 1Dipartimento di Scienze Mediche e Chirurgiche, Clinica Medica, Università Politecnica delle Marche, Ancona, Italy. a.gabrielli@univpm.it

Current Opinion in Immunology
|December 18, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Utility of the diaphragm assessment in acute decompensated heart failure: a case series and a proof-of-concept study.

Internal and emergency medicine·2026
Same author

How Has the COVID-19 Pandemic Been Associated with Emergency Department Leave Without Being Seen Rates? A Comparison Between Hospitals in Ancona (Italy) and Gran Canaria (Spain).

Medicina (Kaunas, Lithuania)·2026
Same author

The role of integrated gastro-rheumatological care in IBD-associated Spondyloarthritis in achieving joint-gut remission: Four-year outcomes from the real-world SPIB cohort.

Seminars in arthritis and rheumatism·2026
Same author

Safety and effectiveness of tocilizumab in systemic sclerosis: a multicentre French-Italian study.

RMD open·2026
Same author

Expert Perspectives: Defining and Managing Progressive Pulmonary Fibrosis in Systemic Sclerosis.

Arthritis & rheumatology (Hoboken, N.J.)·2026
Same author

Real-world clinical experience with upadacitinib in a cohort of Italian patients with axial spondyloarthritis.

Frontiers in pharmacology·2026
Same journal

Noncanonical ion channel signaling in neurovascular barrier regulation and immune cell trafficking.

Current opinion in immunology·2026
Same journal

A blind spot of human T cell immunology: epitope specificity in secondary lymphoid organs.

Current opinion in immunology·2026
Same journal

Germinal center responses at barrier organ sites.

Current opinion in immunology·2026
Same journal

Ocular sarcoidosis: from clinical signs to targeted interventions.

Current opinion in immunology·2026
Same journal

On or within: spatial determinants of antigen handling in the nasal turbinates.

Current opinion in immunology·2026
Same journal

Decoding the complexity of intestinal immunity with spatial transcriptomics.

Current opinion in immunology·2026
See all related articles

Novel agonistic autoantibodies targeting the PDGF receptor offer new insights into systemic sclerosis (scleroderma) pathogenesis. These autoantibodies may link the immune system to fibrosis, a key feature of scleroderma.

Area of Science:

  • Immunology
  • Rheumatology
  • Pathophysiology

Background:

  • Systemic sclerosis (scleroderma) involves widespread vascular injury and organ fibrosis.
  • Autoantibodies are common in scleroderma patients, correlating with clinical features.
  • The pathogenic role of previously identified autoantibodies in scleroderma remains unproven.

Purpose of the Study:

  • To investigate the role of novel agonistic autoantibodies targeting the PDGF receptor in scleroderma pathogenesis.
  • To explore the intracellular mechanisms linking the immune system to fibrosis in scleroderma.

Main Methods:

  • Identification and characterization of novel autoantibodies.
  • Analysis of autoantibody targets, specifically the PDGF receptor.
  • Investigation of intracellular signaling pathways involved in fibrosis.

Related Experiment Videos

Main Results:

  • Discovery of agonistic autoantibodies targeting the PDGF receptor in scleroderma patients.
  • These autoantibodies provide insight into the molecular pathogenesis of scleroderma.
  • They represent a potential molecular link between the immune system and fibrotic processes.

Conclusions:

  • Novel agonistic autoantibodies targeting the PDGF receptor are implicated in scleroderma pathogenesis.
  • These autoantibodies may drive fibrosis through intracellular mechanisms.
  • Further in vivo validation is required to confirm their pathogenic role in systemic sclerosis.